Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
12. lappuse
... Application " ( IND ) is required . The Food and Drug Administration will offer assistance to any practitioner wishing to submit an Investigational New Drug Application . ( c ) This section does not apply to drugs or their components ...
... Application " ( IND ) is required . The Food and Drug Administration will offer assistance to any practitioner wishing to submit an Investigational New Drug Application . ( c ) This section does not apply to drugs or their components ...
14. lappuse
... application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not more than 0.5 gram ( 7.7 grains ) of anhy- drous sodium gentisate per dosage unit . ( v ) The preparation is labeled with ...
... application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not more than 0.5 gram ( 7.7 grains ) of anhy- drous sodium gentisate per dosage unit . ( v ) The preparation is labeled with ...
15. lappuse
... application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not more than 5 milligrams of dicyclomine hydrochloride per dosage unit , or if it is in liquid form not more than 0.5 mil- ligram ...
... application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation contains not more than 5 milligrams of dicyclomine hydrochloride per dosage unit , or if it is in liquid form not more than 0.5 mil- ligram ...
16. lappuse
... application to the skin , and containing no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The sulfur dioxide and all other components of the preparation meet their professed ...
... application to the skin , and containing no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The sulfur dioxide and all other components of the preparation meet their professed ...
17. lappuse
... application to the skin , and containing no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The pramoxine hydrochloride and all other components of the prepara- tion meet their ...
... application to the skin , and containing no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The pramoxine hydrochloride and all other components of the prepara- tion meet their ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning